KING OF PRUSSIA, PA, 23 April 2025 — United BioSource LLC (UBC), a leading provider of evidence development solutions for the biopharmaceutical industry, today announced it has been named a leader in Everest Group’s Pre-approval Pharmacovigilance (PV) Operations PEAK Matrix® Assessment 2025, while also earning distinction as a major contender in Everest Group’s Post-approval PV Operations PEAK Matrix® Assessment 2025. These designations reflect UBC’s deep understanding of the evolving safety landscape and regulations, and validates its technology suite that enables effective risk management, patient safety and regulatory compliance.
“Establishing a technically advanced, audit-ready PV operation that prioritizes quality and compliance is essential for the success of all life science companies,” remarked Geraldine Aubes, Executive Director, Global Head of UBC Pharmacovigilance. “This distinction verifies UBC’s commitment to maintain patient safety and ensure high regulatory compliance throughout the drug development and commercialization process.”
The success of a PV operation is essential for all life science companies, and is shaped by evolving regulatory requirements, rising case volumes, complex safety profiles, and the need for global compliance. UBC offers a flexible, collaborative approach to delivering tailored PV programs that support regulatory obligations, ensure global safety compliance, and protect patient wellbeing. UBC’s comprehensive solutions include strategic partnerships, customized programs, global regulatory expertise, end-to-end PV services, expert case processing and reporting, in-depth literature reviews, and high-quality safety writing.
The Everest Group PEAK Matrix is a proprietary framework used to evaluate market success and technology services based on performance, experience, ability, and knowledge. Service providers are comparatively assessed on their market impact and delivery capabilities.
In this year’s assessment, Everest Group evaluated 29 leading PV operations providers featured on the PV Operations PEAK Matrix. Each provider profile presents a holistic view of service focus, solution offerings, and domain-specific investments. The analysis is based on Everest Group’s annual RFI (request for information) process for calendar year 2024, along with PV provider, client reference checks, and ongoing market research.
“Pharmacovigilance isn’t just about compliance — it’s about safeguarding lives with precision, expertise, and innovation. This recognition by Everest Group is a testament to our pursuit of excellence,” said Natalie O’Donnell, Senior Vice President and Head of Safety and Risk Management at UBC. “We’re not just keeping pace with evolving safety demands — we’re helping our clients stay ahead of them.”
To read about Everest Group’s Pre-approval Pharmacovigilance Operations PEAK Matrix Assessment 2025, visit here. To read about UBC’s pharmacovigilance solutions, visit here.
About UBC
United BioSource LLC (UBC) is the leading provider of evidence development solutions with expertise in uniting evidence and access. UBC helps biopharma mitigate risk, address product hurdles, and demonstrate safety, efficacy, and value under real-world conditions. Underpinned by our scientific expertise, data and analytics, and innovative technologies, we offer our customers flexible solutions generating the relevant real-world data necessary to make more informed decisions earlier, meet stakeholder requirements, and, ultimately, drive better patient outcomes. For additional information, visit www.ubc.com.
Media Inquiries
Maggie Williard
Account Executive, HDMZ
maggie.williard@hdmz.com
(312) 506-5239
